多年心血付诸东流后，默沙东押宝下一个竞争焦点

CPHI制药在线2024-12-26

关注并星标CPHI制药在线12月16日，默沙东在其官网宣布，正式终止其抗TIGIT抗体Vibostolimab和抗LAG-3抗体Favezelimab的开发，这一调整标志着默沙东在免疫检查点抑制剂领域的多年心血付诸东流。两天后，默沙东宣布押注的下一个目标。12月18日，默沙东宣布与国内翰森制药合作，默沙东将获得后者一款在研口服小分子GLP-1受体激动剂（GLP-1RA）HS-10535的全球独家...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2494854984?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-26 19:21","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2494854984","market":"us","top_or_hot":-1,"title":"多年心血付诸东流后，默沙东押宝下一个竞争焦点","media":"CPHI制药在线","content":"<div>\n<p>关注并星标CPHI制药在线12月16日，默沙东在其官网宣布，正式终止其抗TIGIT抗体Vibostolimab和抗LAG-3抗体Favezelimab的开发，这一调整标志着默沙东在免疫检查点抑制剂领域的多年心血付诸东流。两天后，默沙东宣布押注的下一个目标。12月18日，默沙东宣布与国内翰森制药合作，默沙东将获得后者一款在研口服小分子GLP-1受体激动剂（GLP-1RA）HS-10535的全球独家...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226200237a20a6dc9&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>多年心血付诸东流后，默沙东押宝下一个竞争焦点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n多年心血付诸东流后，默沙东押宝下一个竞争焦点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-26 19:21 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226200237a20a6dc9&s=b><strong>CPHI制药在线</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>关注并星标CPHI制药在线12月16日，默沙东在其官网宣布，正式终止其抗TIGIT抗体Vibostolimab和抗LAG-3抗体Favezelimab的开发，这一调整标志着默沙东在免疫检查点抑制剂领域的多年心血付诸东流。两天后，默沙东宣布押注的下一个目标。12月18日，默沙东宣布与国内翰森制药合作，默沙东将获得后者一款在研口服小分子GLP-1受体激动剂（GLP-1RA）HS-10535的全球独家...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226200237a20a6dc9&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999002224.SGD","symbol_name":"Allianz Global High Payout SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226200237a20a6dc9&s=b","article_id":"2494854984","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226200237a20a6dc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2494854984","pubTimestamp":1735212101,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"关注并星标CPHI制药在线12月16日，默沙东在其官网宣布，正式终止其抗TIGIT抗体Vibostolimab和抗LAG-3抗体Favezelimab的开发，这一调整标志着默沙东在免疫检查点抑制剂领域的多年心血付诸东流。两天后，默沙东宣布押注的下一个目标。而默沙东要押注的下一个竞争焦点，也为创新药企带来启发。目前，距离K药专利到期只剩下三年左右的时间，默沙东在为寻找下一个重磅炸弹焦虑，不过并未取得理想成绩。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999002224.SGD":"Allianz Global High Payout SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999002232.USD":"Allianz Global High Payout USD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4559":"巴菲特持仓","MRK":"默沙东","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4588":"碎股","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4550":"红杉资本持仓","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0861579265.USD":"联博低波幅策略股票基金A","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H"},"translate_title":"After years of hard work wasted, Merck is betting on the next competitive focus","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1},"content_text":"关注并星标CPHI制药在线12月16日，默沙东在其官网宣布，正式终止其抗TIGIT抗体Vibostolimab和抗LAG-3抗体Favezelimab的开发，这一调整标志着默沙东在免疫检查点抑制剂领域的多年心血付诸东流。两天后，默沙东宣布押注的下一个目标。12月18日，默沙东宣布与国内翰森制药合作，默沙东将获得后者一款在研口服小分子GLP-1受体激动剂（GLP-1RA）HS-10535的全球独家许可权，翰森制药暂时保留HS-10535在中国的控制权，合作总金额高达20亿美元。频繁的业务调整背后，是默沙东对K药（帕博利珠单抗）即将迎来专利悬崖的焦虑。而默沙东要押注的下一个竞争焦点，也为创新药企带来启发。TIGIT、LAG-3靶点失利，多年心血打水漂此次默沙东终止开发的其中一款产品Vibostolimab，是一种抗TIGIT抗体。TIGIT是一种表达在T细胞和NK细胞上的抑制性受体，属于免疫球蛋白超家族。它可以与CD155和CD112等配体结合，从而抑制NK细胞和T细胞对肿瘤细胞的杀伤作用。因此，针对TIGIT的抗体或者其他药物可以用来阻断TIGIT信号通路，从而增强机体对肿瘤细胞的免疫反应，提高抗肿瘤活性。基于TIGIT这一作用机理，TIGIT靶点被视为下一个爆点，引来多家药企竞逐，但并没有药企成功。在TIGIT赛道，默沙东和罗氏是最积极开发的，两家药企已经坚持开发了八九年，双方竞逐多年，但都未修成正果。默沙东的Vibostolimab曾经历多次失败。2023年12月，默沙东终止了KeyVibe-002试验，该试验旨在评估使用K药+Vibostolimab联合疗法与标准治疗多西他赛相比，在转移性NSCLC患者中的疗效。结果显示，与仅接受多西他赛治疗的患者相比，Vibostolimab+K药组未改善中位PFS和中位OS。2024年5月，默沙东宣布终止正在进行的K药+Vibostolimab对比K药单药辅助治疗手术切除后的IIB-IV期高危黑色素瘤患者的研究。最终，基于现有的KeyVibe系列研究的全部数据，默沙东决定终止Vibostolimab的开发计划。另一个被终止研究的药物是抗LAG-3抗体Favezelimab，是默沙东自研的一款靶向淋巴细胞活化基因3（LAG-3）的抗体药物，旨在通过阻止LAG-3与其主要配体、主要组织相容性复合体（MHC）II类分子结合来恢复T细胞效应器功能。对于Favezelimab，默沙东开展了Favezelimab+K药复方治疗PD-L1阳性微卫星稳定（MSS）转移性结直肠癌（mCRC）患者的III期KEYFORM-007研究，但在最终的预先指定分析中未能达到主要终点。除了KEYFORM-007研究，默沙东还开展了两项III期研究评估Favezelimab+K药复方的治疗潜力。但基于现有的所有临床数据，默沙东决定终止Favezelimab的临床开发项目。事实上，在原先的开发计划里，Vibostolimab和Favezelimab都是与K药联合开展的，如今均被放弃开发，默沙东的下一个研发焦点押注在哪里？口服GLP-1是下一个重磅炸弹吗？12月18日，默沙东宣布与国内翰森制药就一种在研口服小分子GLP-1受体激动剂HS-10535达成合作协议，合作总金额高达20亿美元。目前，翰森制药尚未对外披露过HS-10535的研发进度及具体适应症等。从默沙东方面对HS-10535的期待来看，其适应症或与减重、心脏代谢疾病相关。GLP-1相关产品作为减重药物，对制药公司的吸引力巨大。诺和诺德、礼来凭借GLP-1产品司美格鲁肽、替尔泊肽赚取大额利润。今年前三季度，司美格鲁肽销售额为206亿美元，替尔泊肽达到了110亿美元，并且增长还在持续。因此，默沙东想要找到下一个“K药”，GLP-1的布局必不可少。事实上，默沙东早在2010年就开始布局GLP-1项目，目前尚未有产品成功上市。此次转向口服小分子领域，或许是一次弯道超车的机会。目前，口服司美格鲁肽片剂（Rybelsus）仍是唯一上市的口服GLP-1药物。Rybelsus采用了SNAC技术，在额外增加了300mg SNAC分子后，能够瞬时提高胃部pH，特定浓度下促进胃黏膜的跨细胞吸收。Rybelsus从2019年上市起，销量一直非常可观。目前在口服GLP-1R激动剂领域，礼来的Orforglipron进度最快。Orforglipron最初由中外制药研发，2018年，礼来以5000万美元首付款获得其全球开发和商业化权益。在II期临床试验中，Orforglipron展现出了对肥胖或超重患者体重管理的显著效果。国内恒瑞医药的HRS-7535也是一款口服小分子GLP-1受体激动剂，主要针对2型糖尿病和减重，目前处于Ⅱ期临床试验阶段。值得一提的是，即使受试者基线体重较低（67.6kg），连续给药HRS-7535 4周后依旧可以观察到体重下降4.38kg的明显减重效果（vs安慰剂组0.8kg）。今年2月，HRS-7535获NMPA批准开展用于减重适应症的Ⅱ期临床研究。闻泰医药的口服小分子GLP-1RA VCT220已在国内开展针对肥胖症和超重患者的 III 期临床研究，据先前的II期临床研究结果表明，CX11 显示出比当前同类药物更有竞争力的减重效果，并展现出良好的安全性和耐受性。目前，距离K药专利到期只剩下三年左右的时间（2028年），默沙东在为寻找下一个重磅炸弹焦虑，不过并未取得理想成绩。尤其是被寄予厚望的TIGIT、LAG3、GLP-1等靶点的研发失利，使得默沙东更加着急。此次把宝押在口服GLP-1小分子上，或许是默沙东弯道超车的机会。参考来源：1.Merck provides update on KeyVibe and Keyform Clinical development programs evaluating investigational vibostolimab and favezelimab fixed dose combinations with Pembrolizumab.2.Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.3.https://www.empr.com/home/news/mycapssa-octreotide-approved-capsules-acromegaly-patients-chiasma/.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2494854984"}